Net-Zero Pharma Is a Myth Without Global Alignment on Scope 3 Emissions
Pharma’s net-zero promises hide deeper gaps. Scope 3 emissions and pollution reveal why true sustainability remains elusive.
Thaddeus Anim-Somuah | Aug 31, 2025
Preventing FDA Warning Letters - Building a Compliance-First Culture
Learn how a compliance - first culture, proactive audits, and strong training programs can help you avoid costly FDA warning letters.
Ravindra Warang | Aug 12, 2025
Digitization in Pharma - Risk or Opportunity?
A deep dive into pharma’s digitization journey—challenges, progress, and what the future demands.
Chandrashekhar Rao | Aug 05, 2025
FDA Accelerated Approval What’s Changing and Why It Matters for Rare Diseases
Exploring the FDA’s evolving Accelerated Approval pathway and its implications for pharma innovation and regulatory alignment.
Dawn Stephenson | Jul 31, 2025
Building Thinking Plants: Operational Excellence as a Culture Shift in Pharma
How Operational Excellence and Lean Six Sigma can simultaneously improve quality, reduce costs, and transform pharma culture.
Abhay Kumar Srivastava | Jul 04, 2025
Subscribe to our Newsletter!
Be the first to get exclusive offers and the latest news